Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK

NCT05266846 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

78

Enrollment

OTHER

Sponsor class

Conditions

ALK Gene Mutation
Lung Adenocarcinoma
Immunotherapy

Interventions

DRUG: Pembrolizumab injection

Sponsor

Hunan Province Tumor Hospital